

## EXHIBIT 115



Pharmaceuticals

April 18, 2015

Drug Enforcement Administration  
Attn: Donetta Spears  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

Osborn Drugs  
103 S Main  
Miami, OK 74354  
RO0470601

Date	Product	NDC	Size	Quantity	Total Dosage Units
4/8/2016	BUPREN/NALOXONE SL TAB 8MG/2MG 30	00093-5721-56	30	48	1,440

**Redaction - Other Teva Product**

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

February 21, 2018

Drug Enforcement Administration  
Attn: Luke Braxton  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

**Redaction - Other Teva Product**

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



---

**Administrative Offices:**

TEVA PHARMACEUTICALS USA  
1090 Horsham Road, PO Box 1090  
North Wales, PA 19454-1090

---

February 13, 2013

Drug Enforcement Administration  
Attn: Donetta Spears  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

RE: Suspicious Order Report

Dear Ms. Spears,

This report is submitted to you in accordance with the requirements of 21C.F.R. § 1301.74(b). The following Controlled Substance order(s) has been cancelled by Teva Pharmaceuticals. The order quantity is not within the customer's normal purchasing pattern.

Date	Company	Address	DEA Registration	Product	Quantity
2/5/13	Capital Wholesale Drug	873 Williams Avenue Grandview Heights, OH 43212		Buprenorphine HCl Sublingual Tab 2MG 30	36 bottles

If you have any questions, please feel free to contact me via telephone at 267-468-4346 or via email at Kevin.kreutzer@tevapharm.com.

Sincerely,  
Teva Pharmaceuticals

Kevin Kreutzer  
Manager, Suspicious Order Monitoring



Pharmaceuticals

January 17, 2018

Drug Enforcement Administration

Attn: Luke Braxton

Diversion Program Manager

William J. Green Federal Building

600 Arch Street, Room 10224

Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC NJ  
116 LEHIGH DRIVE  
FAIRFIELD, NJ 07004  
RR0480676

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/16/2018	ACETAMINOPHEN & CODEINE TB 300/15MG	00093-0050-01	100	20	2,000
1/16/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	10	1,000
1/16/2018	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-01	100	70	7,000
Redaction - Other Teva Product					
1/16/2018	BUTAL/ASA/CAF/COD 50/325/40/30MG CAP	00591-3546-01	100	11	1,100

**Redaction - Other Teva Product**



Pharmaceuticals

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

January 17, 2018

Drug Enforcement Administration  
Attn: Luke Braxton  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC  
50 JETVIEW DRIVE  
ROCHESTER, NY 14624  
PR0003032

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/17/2018	GABAPENTIN 300MG CAPSULES	45963-0556-11	100	75	7,200
1/17/2018	GABAPENTIN 100MG CAPSULES	45963-0555-50	500	48	24,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

January 18, 2018

Drug Enforcement Administration

Attn: Luke Braxton

Diversion Program Manager

William J. Green Federal Building

600 Arch Street, Room 10224

Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC  
50 JETVIEW DRIVE  
ROCHESTER, NY 14624  
PR0003032

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/18/2018	LORAZEPAM 1MG TABLETS	00591-0241-01	100	48	4,800
1/18/2018	BUPREN/NALOX 2/0.5MG TABLETS 30 BL	00228-3154-73	30	24	720
1/18/2018	LORAZEPAM 2MG TABLETS 100	00591-0242-01	100	12	1,200
1/18/2018	MODAFINIL 100MG TABLETS 30	00591-3499-30	30	18	540
1/18/2018	OXAZEPAM 15MG CAPSULES 100	00228-2069-10	100	36	3,600
1/18/2018	TEMAZEPAM 15MG CAPSULES 100	00228-2076-10	100	24	2,400
1/18/2018	BUTAL/APAP/CAF/COD 50/325/40/30MG CAP100	00591-3220-01	100	1	100
1/18/2018	CARISOPRODOL 350MG TABLETS 100	00591-5513-01	100	11	1,100
1/18/2018	ESTAZOLAM 2MG TABLETS 100	00591-0745-01	100	1	100
1/18/2018	LORAZEPAM 0.5MG TABLETS 500	00591-0240-05	500	36	18,000
1/18/2018	LORAZEPAM 0.5MG TABLETS 1000	00591-0240-10	1000	54	54,000
1/18/2018	LORAZEPAM 1MG TABLETS 1000	00591-0241-10	1000	18	18,000
1/18/2018	LORAZEPAM 1MG TABLETS 500	00591-0241-05	500	12	6,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.





Pharmaceuticals

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

February 6, 2018

Drug Enforcement Administration  
Attn: Luke Braxton  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC NJ  
116 LEHIGH DRIVE  
FAIRFIELD, NJ 07004  
RR0480676

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/30/2018	GABAPENTIN 400MG CAPSULES	45963-0557-50	500	12	6,000
1/30/2018	GABAPENTIN 300MG CAPSULES	45963-0556-50	500	24	12,000
1/30/2018	GABAPENTIN 100MG CAPSULES	45963-0555-50	500	24	12,000
1/30/2018	GABAPENTIN TABLETS 600MG	00093-4443-05	500	1	500
1/30/2018	GABAPENTIN TABLETS 600MG	00093-4443-10	1000	6	6,000
2/5/2018	ADIPEX-P TABLETS	57844-0009-01	100	12	1,200

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

February 6, 2018

Drug Enforcement Administration  
Attn: Luke Braxton  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC  
50 JETVIEW DRIVE  
ROCHESTER, NY 14624  
PR0003032

Date	Product	NDC	Size	Quantity	Total Dosage Units
2/5/2018	NUVIGIL TAB 250MG	63459-0225-30	30	12	360

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

February 7, 2018

Drug Enforcement Administration  
Attn: Luke Braxton  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC  
50 JETVIEW DRIVE  
ROCHESTER, NY 14624  
PR0003032

Date	Product	NDC	Size	Quantity	Total Dosage Units
2/6/2018	CHLORDIAZEPOXIDE HCL CAPSULES 25MG	00555-0159-04	500	6	3,000

Additionally, pursuant to previous investigation, we have suspended all sales of controlled substances to this registrant. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

March 30, 2018

Drug Enforcement Administration  
Attn: Luke Braxton  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

ROCHESTER DRUG CO-OPERATIVE INC NJ  
116 LEHIGH DRIVE  
FAIRFIELD, NJ 07004  
RR0480676

Date	Product	NDC	Size	Quantity	Total Dosage Units
<b>Redaction - Other Teva Product</b>					
3/27/2018	FENTORA TB 800MCG	63459-0548-28	28	12	336

We have previously suspended all sales of controlled substances to this registrant. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

June 25, 2015

Drug Enforcement Administration  
Attn: Donetta Spears  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

Richie Pharmacal LLC  
119 State Avenue  
Glasgow, KY 42141  
RR0355683

Date	Product	NDC	Size	Quantity	Total Dosage Units
6/23/2015	ESTAZOLAM TABLETS 2MG	00093-0130-01	100	36	3,600
6/24/2015	BUPRENORPHINE/NALOXONE 2MG/0.5MG	00093-5720-56	30	12	360
6/24/2015	BUPRENORPHINE/NALOXONE 8MG/2MG	00093-5721-56	30	288	8,640

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
Diversion Operations Manager  
Teva Pharmaceuticals



Pharmaceuticals

July 31, 2015

Drug Enforcement Administration  
Attn: Donetta Spears  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

Osborn Drugs  
103 S Main  
Miami, OK 74354  
RO0470601

Date	Product	NDC	Size	Quantity	Total Dosage Units
5/4/2015	ACETAMINOPHEN & CODEINE TB 300/60MG 100	00093-0350-01	100	60	6,000
Redaction - Other Teva Product		Redaction - Other Teva Product			

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

August 19, 2015

Drug Enforcement Administration  
Attn: Donetta Spears  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

BLOODWORTH WHOLESALE DRUGS  
2128 Yank Lamb Drive  
Tifton, GA 31794  
PB0167127

Date	Product	NDC	Size	Quantity	Total Dosage Units
7/24/2015	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	50	5,000
6/11/2015	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-10	1000	192	192,000

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals





Pharmaceuticals

April 19, 2017

Drug Enforcement Administration  
Attn: Donetta Spears  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

D-V Medical Supply  
2000 W. 135<sup>th</sup> Street  
Gardena, CA 90249  
RD0233938

Date	Product	NDC	Size	Quantity	Total Dosage Units
4/5/2017	BUPRENORPHINE 8MG SL TABLETS 30	00228-3153-03	30	24	720
4/5/2017	CARISOPRODOL 350MG TABLETS 500	00591-5513-05	500	72	36,000
4/5/2017	CARISOPRODOL 350MG TABLETS 500	00591-5513-05	500	72	36,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

April 19, 2017

Drug Enforcement Administration  
Attn: Donetta Spears  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

D-V Medical Supply  
2000 W. 135<sup>th</sup> Street  
Gardena, CA 90249  
RD0233938

Date	Product	NDC	Size	Quantity	Total Dosage Units
4/5/2017	BUPRENORPHINE 8MG SL TABLETS 30	00228-3153-03	30	24	720
4/5/2017	CARISOPRODOL 350MG TABLETS 500	00591-5513-05	500	72	36,000
4/5/2017	CARISOPRODOL 350MG TABLETS 500	00591-5513-05	500	72	36,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

April 19, 2017

Drug Enforcement Administration  
Attn: Donetta Spears  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

EMED Medical Company  
11551 Adie Rd  
Maryland Heights, MO 63043-6304  
RE0357271

Date	Product	NDC	Size	Quantity	Total Dosage Units
4/11/2017	HYDROCODONE/APAP 10/325MG TAB 500	00591-2612-05	500	270	135,000
4/14/2017	HYDROCODONE/APAP 10/325MG TAB 500	00591-2612-05	500	270	135,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

June 8, 2017

Drug Enforcement Administration  
Attn: Donetta Spears  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Ms. Spears,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

EMED Medical Company  
11551 Adie Rd  
Maryland Heights, MO 63043-6304  
RE0357271

Date	Product	NDC	Size	Quantity	Total Dosage Units
4/28/2017	CARISOPRODOL 350MG TAB 500	00591-5513-05	500	48	24,000

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant, pending any further investigation, if it shall become warranted. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

August 22, 2017

Drug Enforcement Administration  
Attn: Donetta Spears  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

## Redaction-Other Teva Product

Date	Product	NDC	Size	Quantity	Total Dosage Units
Redaction-Other Teva Product					

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

April 18, 2018

Drug Enforcement Administration

Attn: Luke Braxton

Diversion Program Manager

William J. Green Federal Building

600 Arch Street, Room 10224

Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

DIXON-SHANE LLC  
D/B/A R & S NORTHEAST LLC  
10049 SANDMEYER LANE  
PHILADELPHIA, PA 19116  
RD0289656

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/17/2018	BUPREN/NALOX 8/2MG SL TABLETS	00228-3155-73	30	24	720
1/17/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	10	1,000

**Redaction - Other Teva Product**

2/2/2018	HYDROCODONE/APAP 10/325MG TAB	00591-2612-05	500	12	6,000
----------	-------------------------------	---------------	-----	----	-------

**Redaction - Other Teva Product**

2/9/2018	HYDROCODONE/APAP 10/325MG TAB	00591-2612-05	500	12	6,000
----------	-------------------------------	---------------	-----	----	-------

**Redaction - Other Teva Product**

3/15/2018	BUPREN/NALOX 8/2MG SL TABLETS	00228-3155-73	30	24	720
3/21/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	10	1,000
3/29/2018	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-01	100	10	1,000

**Redaction - Other Teva Product**



Pharmaceuticals

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

April 18, 2018

Drug Enforcement Administration

Attn: Luke Braxton

Diversion Program Manager

William J. Green Federal Building

600 Arch Street, Room 10224

Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

DIXON-SHANE LLC  
D/B/A R & S NORTHEAST LLC  
10049 SANDMEYER LANE  
PHILADELPHIA, PA 19116  
RD0289656

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/17/2018	BUPREN/NALOX 8/2MG SL TABLETS	00228-3155-73	30	24	720
1/17/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	10	1,000

## Redaction - Other Teva Product

2/2/2018	HYDROCODONE/APAP 10/325MG TAB	00591-2612-05	500	12	6,000
----------	-------------------------------	---------------	-----	----	-------

## Redaction - Other Teva Product

2/9/2018	HYDROCODONE/APAP 10/325MG TAB	00591-2612-05	500	12	6,000
----------	-------------------------------	---------------	-----	----	-------

## Redaction - Other Teva Product

3/15/2018	BUPREN/NALOX 8/2MG SL TABLETS	00228-3155-73	30	24	720
3/21/2018	ACETAMINOPHEN & CODEINE TB 300/30MG	00093-0150-01	100	10	1,000
3/29/2018	ACETAMINOPHEN & CODEINE TB 300/60MG	00093-0350-01	100	10	1,000

## Redaction - Other Teva Product





Pharmaceuticals

Additionally, pursuant to our investigation, we have suspended all sales of controlled substances to this registrant. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

January 16, 2018

Drug Enforcement Administration  
Attn: Luke Braxton  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of controlled substance orders we have deemed to be suspicious. The orders were placed by the following registrant:

DIXON-SHANE LLC  
D/B/A R & S NORTHEAST LLC  
10049 SANDMEYER LANE  
PHILADELPHIA, PA 19116  
RD0289656

Date	Product	NDC	Size	Quantity	Total Dosage Units
1/10/2018	OXYCODONE HCL 30MG TABLETS	00228-2879-11	100	48	4,800

If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals



Pharmaceuticals

December 13, 2017

Drug Enforcement Administration  
Attn: Luke Braxton  
Diversion Program Manager  
William J. Green Federal Building  
600 Arch Street, Room 10224  
Philadelphia, PA 19106

Re: Suspicious Order Report

Dear Mr. Braxton,

In accordance with 21C.F.R. § 1301.74(b), I am submitting this report of orders we have deemed to be suspicious. The orders were placed *by* the following company:

AVA KEROLOS  
GOOD SAMARITAN PHARMACY  
33130 US HIGHWAY 19N  
PALM HARBOR, FL 34683  
FA5044691

*From* the following company:

DIXON-SHANE LLC  
D/B/A R & S NORTHEAST LLC  
10049 SANDMEYER LANE  
PHILADELPHIA, PA 19116  
RD0289656

Date	Invoice	Product	NDC	Size	Quantity	Total Dosage Units
8/22/2017	140839	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
8/22/2017	140840	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
8/23/2017	140884	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
8/30/2017	141599	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
9/7/2017	142238	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
9/14/2017	142886	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
9/20/2017	143484	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
9/27/2017	144187	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
10/5/2017	144882	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
10/11/2017	145267	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
10/18/2017	145843	OXYCODONE HCL 30MG TAB	00228-2879-11	100	1	100
10/27/2017	146595	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600
10/27/2017	146598	OXYCODONE HCL 30MG TAB	00228-2879-11	100	5	500
11/1/2017	147170	OXYCODONE HCL 30MG TAB	00228-2879-11	100	6	600

## EXHIBIT 115



Pharmaceuticals

Accordingly, Teva has suspended DIXON-SHANE, LLC's ability to purchase all oxycodone products pending the results of our investigation. If you have any questions or concerns, or need any further information, feel free to contact me. My office number is 215.293.6378.

Sincerely,

Joseph Tomkiewicz  
DEA Compliance Manager  
Teva Pharmaceuticals